Anervea
AlfaAccess
EU Reimbursement Prediction
Pipeline assets
Prototype for
Menarini EU
Market Access Team
Powered by GRG Health expert intelligence (400,000+ experts)

Portfolio overview

Haematology-oncology pipeline · EU5 · 18 March 2026

Pipeline assets
4
Critical priority
2
Active alerts
5
Portfolio insights
4
GRG experts active
112
MEN-1703SelinaciclibPhase 32 alerts
CDK7 inhibitor
R/R CLL/SLL — BTK-resistant
72
Moderate
Submission target
Q4 2026
EU launch target
Q3 2027
NPV scenario Δ
€ 156M
DE●
FR●
UK
IT
ES
↑ OS maturity 58% — G-BA submission delay vs proceed decision required Q2 2026
MEN-2856Navitoclax-MPhase 3Orphan1 alert
BCL-2/BCL-XL dual inhibitor
Newly diagnosed AML — TP53 mutated, unfit IC
84
Strong
Submission target
Q2 2027
EU launch target
Q1 2028
NPV scenario Δ
€ 203M
DE
FR
UK●
IT
ES
↑ NGS companion diagnostic regulatory approval timeline must precede AIFA submission
MEN-4092Cenacitamab-MPhase 31 alert
CD3×CD20 bispecific T-cell engager
R/R DLBCL — after ≥2 lines of therapy
61
Moderate
Submission target
Q3 2027
EU launch target
Q2 2028
NPV scenario Δ
€ 91M
DE●
FR
UK
IT
ES
↑ Immature OS 52% — G-BA Minor likely at current maturity. Submission delay strongly recommended
MEN-3344MenarfenibPhase 2Orphan1 alert
Menin inhibitor (KMT2A/NPM1-mutated)
R/R AML — NPM1-mutated or KMT2A-rearranged, post-HMA failure
48
At risk
Submission target
Q1 2029
EU launch target
Q4 2029
NPV scenario Δ
TBD
DE
FR
UK
IT
ES
↑ Phase III design decision — biomarker selection must be locked before JSC request. Decision needed Q2 2026

Risk score reflects combined EU5 HTA outcome probability, evidence maturity, competitive landscape, and GRG methodology sentiment signals. Click any asset for full EU5 analysis.